Oncotelic Therapeutics, Inc. and Sapu Bioscience Expand International IP Coverage for OT-101, Strengthening CNS and Neurology Commercialization Pathway

Core Insights - Oncotelic Therapeutics and Sapu Bioscience have made significant advancements in their global intellectual property portfolio for OT-101, enhancing protection across neurology, oncology, and CNS drug delivery [1][5] Group 1: OT-101 Overview - OT-101 is a clinical-stage therapeutic targeting TGF-β, previously tested in various oncology indications such as glioblastoma and pancreatic cancers, and is now being advanced for CNS applications [2] - The compound has also been investigated for use in Acute Respiratory Distress Syndrome (ARDS) and COVID-19-related inflammatory conditions [2] Group 2: Parkinson's Disease Developments - In Australia, the company has received allowed patent claims for OT-101 specifically for treating Parkinson's Disease, including related sleep disorders like excessive daytime sleepiness and insomnia [3] Group 3: Intracranial Delivery Device - Utility model patents for a device enabling continuous intracranial infusion of pharmaceutical compositions have been granted in China and Germany, effective from April 1, 2025, and extending through 2033 [4] Group 4: Strategic Impact of IP Developments - The new IP developments create an integrated commercialization platform for OT-101, combining therapeutic claims in neurology with delivery-device protection, enhancing its strategic value for future partnerships and commercialization [5][8] Group 5: Patent Wall Strategy - Oncotelic is constructing a multi-layered global "Patent Wall" around OT-101, covering therapeutic use, CNS delivery methods, device administration, dosing regimens, combination therapies, and biomarker-driven patient selection, which complicates replication and strengthens long-term commercial viability [7] Group 6: Company Background - Oncotelic Therapeutics is focused on developing oncology and immunotherapy products, aiming to address high unmet needs in cancer and rare pediatric indications with innovative therapeutic candidates [9][10]